Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00651612 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 604
- Enrollment target
NCT00651612 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 604 participants.
The verdict
NCT00651612, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 604 participants
- Enrollment target
Study Summary
This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients
Interventions
- DRUG Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
- DRUG Concurrent brimonidine 0.2% and 0.5% timolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 604 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00651612
The ClinicalTrials.gov registry entry for NCT00651612 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 604 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution is the first listed.
NCT00651612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00651612 about?
NCT00651612 is a clinical study titled "Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients". This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients
What is the current status of trial NCT00651612?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 604 participants. The study started on 2005-11. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00651612?
The interventions under investigation include: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution (DRUG), Concurrent brimonidine 0.2% and 0.5% timolol (DRUG).
Who is sponsoring clinical trial NCT00651612?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.